OnCore Login

Return to Trial Database

HCRN-GU14-202

Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib

Status

Study Completed

Cancer Type(s)

Prostate

Study Contact

Publications

Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC)
  • JP Flores, P Mathew

Trial Locations

All sites in which the trial HCRN-GU14-202 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278